Graves orbitopathy: A perspective

Nature Reviews Endocrinology

Volumn 5, Issue 6, 2009, Pages 312-318

  Perros, Petros ^a   Krassas, Gerasimos E ^b  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

^b PANAGIA GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ANTITHYROID AGENT; CARBIMAZOLE; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON RECEPTOR 1; IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1; METHYLPREDNISOLONE; PENTOXIFYLLINE; PREDNISOLONE; PREDNISONE; RITUXIMAB; SELENIUM; SOMATOMEDIN C; STEROID; THIAMAZOLE; THYROTROPIN RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR;

CTLA4 GENE; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENDOCRINE OPHTHALMOPATHY; EYE MOVEMENT DISORDER; GENE; GENETIC PREDISPOSITION; HUMAN; ICAM 1 GENE; IFNG GENE; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; MULTIPLE CYCLE TREATMENT; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STEROID THERAPY; THYROIDECTOMY; THYROTOXICOSIS; TNF GENE; TREATMENT OUTCOME; ANIMAL; BIOLOGICAL MODEL; GRAVES DISEASE; ORBIT DISEASE; PATHOLOGY;

ANIMALS; GRAVES DISEASE; HUMANS; MODELS, BIOLOGICAL; ORBITAL DISEASES; STEROIDS;

EID: 68949118009     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2009.61     Document Type: Review

References (60)

1. wiersinga, w. M. Management of Graves' ophthalmopathy. Nat. Clin. Pract. Endocrinol. Metab. 3, 396-404 (2007).
2. Coulter, i. et al. Psychological implications of Graves' orbitopathy. Eur. J. Endocrinol. 157, 127-131 (2007).
3. salvi, M. et al. Patients with endocrine ophthalmopathy not associated with overt thyroid disease have multiple thyroid immunological abnormalities. J. Clin. Endocrinol. Metab. 70, 89-94 (1990).
4. Khoo, D. H. et al. Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels. Thyroid 10, 1093-1100 (2000).
5. Orgiazzi, J. in Graves' Orbitopathy. A Multidisciplinary Approach (eds wiersinga, w. M. & Kahaly, G. J.) 41-56 (Karger Publishers, Basel, 2007).
6. Perros, P. & Kendall-Taylor, P. Biological activity of autoantibodies from patients with thyroidassociated ophthalmopathy: in vitro effects on porcine extraocular myoblasts. Q. J. Med. 84, 691-706 (1992).
7. Perros, P. & Kendall-Taylor, P. Demonstration of thyrotropin binding sites in orbital connective tissue: possible role in the pathogenesis of thyroid-associated ophthalmopathy. J. Endocrinol. Invest. 17, 163-170 (1994).
8. Valyasevi, R. W. et al. Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor. J. Clin. Endocrinol. Metab. 84, 2557-2562 (1999).
9. wakelkamp, i. M. et al. TsH-r expression and cytokine profile in orbital tissue of active vs inactive Graves' ophthalmopathy patients. Clin. Endocrinol. (Oxf.) 58, 280-287 (2003).
10. Boschi, A. et al. Quantification of cells expressing the thyrotropin receptor in extraocular muscles in thyroid associated orbitopathy. Br. J. Ophthalmol. 89, 724-729 (2005).
11. Agretti, P. et al. evidence for protein and mrNA TsHr expression in fibroblasts from patients with thyroid-associated ophthalmopathy (TAO) after adipocytic differentiation. Eur. J. Endocrinol. 152, 777-784 (2005).
12. Gerding, M. N. et al. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin. Endocrinol. (Oxf.) 52, 267-271 (2000).
13. weightman, D. r. et al. Autoantibodies to iGF-i binding sites in thyroid associated ophthalmopathy. Autoimmunity 16, 251-257 (1993).
14. Douglas, R. S. et al. Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis. J. Immunol. 178, 3281-3287 (2007).
15. smith, T. J. et al. Unique attributes of orbital fibroblasts and global alterations in iGF-1 receptor signaling could explain thyroidassociated ophthalmopathy. Thyroid 18, 983-988 (2008).
16. Bednarczuk, T. et al. susceptibility genes in Graves' ophthalmopathy: searching for a needle in a haystack? Clin. Endocrinol. (Oxf.) 67, 3-19 (2007).
17. Jacobson, E. M. & Tomer, Y. The genetic basis of thyroid autoimmunity. Thyroid 17, 949-961 (2007).
18. Perros, P. et al. Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clin. Endocrinol. (Oxf.) 38, 367-372 (1993).
19. wiersinga, w. M. Thyroid-associated ophthalmopathy: pediatric and endocrine aspects. Pediatr. Endocrinol. Rev. 1 (Suppl. 3), 513-517 (2004).
20. Krassas, G. E. et al. Childhood Graves' ophthalmopathy: results of a european questionnaire study. Eur. J. Endocrinol. 153, 515-521 (2005).
21. Krassas, G. e. & wiersinga, w. smoking and autoimmune thyroid disease: the plot thickens. Eur. J. Endocrinol. 154, 777-780 (2006).
22. Pfeilschifter, J. & Ziegler, R. smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin. Endocrinol. (Oxf.) 45, 477-481 (1996).
23. Cawood, T. J. et al. smoking and thyroidassociated ophthalmopathy: a novel explanation of the biological link. J. Clin. Endocrinol. Metab. 92, 59-64 (2007).
24. Dickinson, A. J. & Perros, P. Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin. Endocrinol. (Oxf.) 55, 283-303 (2001).
25. wiersinga, w. M. et al. Clinical assessment of patients with Graves' orbitopathy: the european Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur. J. Endocrinol. 155, 387-389 (2006).
26. Bartley, G. B. & Gorman, C. A. Diagnostic criteria for Graves' ophthalmopathy. Am. J. Ophthalmol. 119, 792-795 (1995).
27. McKeag, D. et al. Clinical features of dysthyroid optic neuropathy: a european Group on Graves' Orbitopathy (eUGOGO) survey. Br. J. Ophthalmol. 91, 455-458 (2007).
28. Hales, I. B. & rundle, F. F. Ocular changes in Graves' disease. A long-term follow-up study. Q. J. Med. 29, 113-126 (1960).
29. Baldeschi, L. et al. reactivation of Graves' orbitopathy after rehabilitative orbital decompression. Ophthalmology 114, 1395-1402 (2007).
30. Bartalena, L. et al. Consensus statement of the european Group on Graves' orbitopathy (eUGOGO) on management of Graves' orbitopathy. Eur. J. Endocrinol. 58, 273-285 (2008).
31. Perros, P. & Kendall-Taylor, P. Medical treatment for thyroid-associated ophthalmopathy. Thyroid 12, 241-244 (2002).
32. Bartalena, L. et al. relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N. Engl. J. Med. 338, 73-78 (1998). (Pubitemid 28042269)
33. Tallstedt, L. et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N. Engl. J. Med. 326, 1733-1738 (1992).
34. Bartalena, L. et al. Glucocorticoids and outcome of radioactive iodine therapy for Graves' hyperthyroidism. Eur. J. Endocrinol. 153, 13-14 (2005).
35. Perros, P. et al. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves' ophthalmopathy. J. Clin. Endocrinol. Metab. 90, 5321-5323 (2005).
36. Järhult, J. et al. Graves' disease with moderate- severe endocrine ophthalmopathy-long-term results of a prospective, randomized study of total or subtotal thyroid resection. Thyroid 15, 1157-1164 (2005).
37. Menconi, F. et al. effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids. J. Clin. Endocrinol. Metab. 92, 1653-1658 (2007).
38. Hart, r. H. Perros, P. Glucocorticoids in the medical management of Graves' ophthalmopathy. Minerva Endocrinol. 28, 223-231 (2003).
39. Kahaly, G. J. et al. randomized, single-blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J. Clin. Endocrinol. Metab. 90, 5234-5240 (2005).
40. Marcocci, C. et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J. Clin. Endocrinol. Metab. 86, 3562-3567 (2001).
41. Hart, R. H. et al. early response to intravenous glucocorticoids for severe thyroid-associated ophthalmopathy predicts treatment outcome. J. Ocul. Pharmacol. Ther. 21, 328-336 (2005).
42. Le Moli, R. et al. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy. Thyroid 17, 357-362 (2007).
43. Perros, P. et al. A questionnaire survey on the management of Graves' orbitopathy in europe. Eur. J. Endocrinol. 155, 207-211 (2006).
44. ramos, H. E. et al. Management of Graves' orbitopathy in Latin America: an international questionnaire study compared with europe. Clin. Endocrinol. (Oxf.) 69, 951-956 (2008).
45. Bradley, E. A. et al. Orbital radiation for Graves ophthalmopathy: a report by the American Academy of Ophthalmology. Ophthalmology 115, 398-409 (2008).
46. wakelkamp, i. M. et al. surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial. Clin. Endocrinol. (Oxf.) 63, 323-328 (2005).
47. Mourits, M. P. et al. radiotherapy for Graves' orbitopathy: randomised placebo-controlled study. Lancet 355, 1505-1509 (2000).
48. Prummel, M. F. et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. J. Clin. Endocrinol. Metab. 89, 15-20 (2004).
49. Baldeschi, L. in Graves' Orbitopathy. A Multidisciplinary Approach (eds wiersinga, w. M. & Kahaly, G. J.) 160-175 (Karger Publishers, Basel, 2007).
50. Neoh, C. & eckstein, A. in Graves' Orbitopathy. A Multidisciplinary Approach, (eds wiersinga, w. M. & Kahaly, G. J) 188-200 (Karger Publishers, Basel, 2007).
51. Finamor, F. E. et al. Pentoxifylline (PTX)--an alternative treatment in Graves' ophthalmopathy (inactive phase): assessment by a diseasespecific quality of life questionnaire and by exophthalmometry in a prospective randomized trial. Eur. J. Ophthalmol. 14, 277-283 (2004).
52. Bartalena, L. et al. Graves' ophthalmopathy: state of the art and perspectives. J. Endocrinol. Invest. 27, 295-301 (2004).
53. Bouzas, e. A. et al. Antioxidant agents in the treatment of Graves' ophthalmopathy. Am. J. Ophthalmol. 129, 618-622 (2000).
54. Dickinson, A. J. et al. Double-blind, placebocontrolled trial of octreotide long-acting repeatable (LAr) in thyroid-associated ophthalmopathy. J. Clin. Endocrinol. Metab. 89, 5910-5915 (2004).
55. Wémeau, J. L. et al. Octreotide (long-acting release formulation) treatment in patients with Graves' orbitopathy: clinical results of a fourmonth, randomized, placebo-controlled, doubleblind study. J. Clin. Endocrinol. Metab. 90, 841-848 (2005).
56. Chang, T. C. & Liao, S. L. slow-release lanreotide in Graves' ophthalmopathy: a double-blind randomized, placebo-controlled clinical trial. J. Endocrinol. Invest. 29, 413-422 (2006).
57. stan, M. N. et al. randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy. J. Clin. Endocrinol. Metab. 91, 4817-4824 (2006).
58. El Fassi, D. et al. Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid 16, 709-710 (2006).
59. Salvi, M. et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur. J. Endocrinol. 156, 33-40 (2007).
60. Nielsen, C. H. et al. B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy: the latest addition to an expanding family. Expert Opin. Biol. Ther. 7, 1061-1078 (2007).